AZD-2327
Abandoned antidepressant drug
From Wikipedia, the free encyclopedia
AZD-2327 is a δ-opioid receptor agonist which was under development for the treatment of depressive disorders and anxiety disorders but was never marketed.[1][2][3][4][5] It is taken by mouth.[1]
- 875647-81-7
1197281-62-1 (hemifumarate)
| |
| Clinical data | |
|---|---|
| Other names | AZD 2327; AZD2327 |
| Routes of administration | Oral[1][2] |
| Drug class | δ-Opioid receptor agonist[1] |
| Identifiers | |
| |
| CAS Number |
|
| PubChem CID | |
| ChemSpider | |
| UNII | |
| ECHA InfoCard | 100.170.827 |
| Chemical and physical data | |
| Formula | C29H35FN4O |
| Molar mass | 474.624 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Pharmacology
The drug showed antidepressant-like and anxiolytic-like effects as well as locomotor-stimulating effects in animal models.[3][4] It had reduced induction of seizures and locomotor hyperactivity compared to other δ-opioid receptor agonists.[3][4] The doses required for stimulant-like activity were 3- to 10-fold greater than the doses that produced antidepressant- and anxiolytic-like effects.[4] The drug appears to have a very low misuse potential based on animal studies.[3][6] In addition to its δ-opioid receptor agonist activity, AZD-2327 has been reported to act as a cytochrome P450 CYP3A4 inhibitor.[7]
It has been found to inhibit the release of norepinephrine caused by anxiety and was able to do so as much as the benzodiazepine diazepam.[8] However, AZD-2327 could be advantageous to benzodiazepines because these drugs often cause rapid tolerance and dependence.[9] In contrast to benzodiazepines, AZD-2327 may have less or no potential for tolerance in terms of its anxiolytic-like effects.[8]
History
AZD-2327 was first described by 2004 and was first described in the scientific literature in 2009.[3] The development of AZD-2327 was discontinued in 2010.[3][1] It reached phase 2 clinical trials for both depressive disorders and anxiety disorders prior to its discontinuation.[1] No reason was given for the discontinuation of its development.[3] However, the drug was found to be ineffective for major depressive disorder in a phase 2 clinical trial.[10][11] AZD-2327 was developed by AstraZeneca.[1][2]